CAR T-cells for lupus and myositis
Part of Bones, joints & muscles, Brain & nervous system, Immune system & allergy, Skin clinical trials.
This trial tests a new treatment using your own immune cells (CAR T-cells) targeted at a marker called CD19. It is for people whose lupus or myositis has not been controlled by other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have either lupus (SLE) for at least 6 months or a muscle inflammation called IIM (myositis).
- Your lupus or myositis has not improved with standard treatments or has come back.
- You have a positive test for CD19 markers on your immune cells.
- You do not have active infections like hepatitis or tuberculosis.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new type of treatment called CAR-T cells, which are specially engineered immune cells that may help control lupus by targeting the cells causing the disease. If you have active lupus despite standard treatments, this therapy might offer a new option to reduce symptoms and improve your condition.
This trial tests a new treatment called CAR-T cell therapy for people with severe autoimmune rheumatic diseases that have not improved with other treatments. The therapy uses your own immune cells, which are modified in a lab to attack the cells causing the disease, potentially reducing symptoms and improving quality of life.
This trial tests a treatment where your own immune cells are modified to attack and destroy lupus-causing B cells. It's for people with lupus (SLE) that hasn't improved with standard treatments.
This study tests a new type of cell therapy called CAR-T cells that target three proteins (CD19, CD22, BCMA) to treat people with autoimmune diseases that have not responded to standard treatments. The goal is to see if it can reset the immune system and reduce disease activity.
This trial tests a new treatment called ICG318 CAR-T, which uses your own immune cells to target and calm the overactive immune system in lupus. It may help people whose lupus has not improved with standard treatments, including those with lupus nephritis (kidney inflammation).
This trial tests a new CAR-T cell treatment for people with lupus who still have moderate to severe symptoms despite trying standard medications. It aims to quickly stop the immune system from attacking the body.
Hear when a new Systemic Lupus Erythematosus (SLE) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.